<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649398</url>
  </required_header>
  <id_info>
    <org_study_id>Brain_MD_Nimodipine</org_study_id>
    <nct_id>NCT04649398</nct_id>
  </id_info>
  <brief_title>Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration</brief_title>
  <official_title>Determination of Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration - a Descriptive Pharmacokinetic/Pharmacodynamics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Science Fund (FWF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients&#xD;
      suffering aneurysmal subarachnoid haemorrhage (SAH), but its mode of action is unknown. Its&#xD;
      beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular&#xD;
      calcium and thereby cellular apoptosis, but higher concentrations might induce marked&#xD;
      systemic hypotension, thereby inducing cerebral ischemia. Since several dosing regimes and&#xD;
      routes of administration with inconclusive superiority exist and since the target site&#xD;
      concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier&#xD;
      - is still not known, it is reasonable to measure nimodipine concentrations within the blood,&#xD;
      cerebrospinal fluid (CSF) and interstitial brain tissue following oral, intra-venous and&#xD;
      intra-arterial administration and correlate intra-arterial nimodipine administration to&#xD;
      measures of cerebral metabolism and oxygenation.&#xD;
&#xD;
      Therefore, the investigators propose to investigate in 30 patients suffering severe&#xD;
      aneurysmal SAH and requiring cerebral microdialysis for cerebral neurochemical monitoring:&#xD;
&#xD;
        -  the ability of nimodipine to penetrate into the brain of neurointensive care patients by&#xD;
           comparing exposure in brain, CSF and plasma, dependent on the route of administration&#xD;
           (i.e. oral, intra-venous, and intra-arterial) and dosing intra-venously (0.5 - 2mg/h)&#xD;
&#xD;
        -  the impact of orally, intra-venously, and intra-arterially delivered nimodipine on&#xD;
           cerebral metabolism, i.e. lactate/pyruvate ratio, pbtO2 and transcranial doppler flow&#xD;
           velocities&#xD;
&#xD;
        -  the effect of oral and intra-venous nimodipine on systemic hemodynamic and cardiac&#xD;
           parameters, using continuous Pulse Contour Cardiac Output (PiCCO) monitoring&#xD;
&#xD;
        -  the penetration properties of ethanol - as an excipient of nimodipine infusion - into&#xD;
           the brain by comparing exposure in brain, CSF and plasma and quantifying the neuronal&#xD;
           exposure to alcohol dependent on blood levels&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral nimodipine concentrations</measure>
    <time_frame>during the intervention</time_frame>
    <description>Area under the concentration-time curve in brain, cerebrospinal fluid and serum, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cerebral ethanol concentrations</measure>
    <time_frame>during the intervention</time_frame>
    <description>Area under the concentration-time curve and maximum concentrations in brain tissue, CSF and blood after intravenous administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cerebral lactate/pyruvate ratio (LPR)</measure>
    <time_frame>during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration</time_frame>
    <description>determined by cerebral microdialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain tissue oxygen tension (pbtO2)</measure>
    <time_frame>during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration</time_frame>
    <description>determined by cerebral parenchymal probes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
    <time_frame>during the intervention</time_frame>
    <description>measured by Pulse Contour Cardiac Output (PiCCO) monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluid responsiveness</measure>
    <time_frame>during the intervention</time_frame>
    <description>measured by Pulse Contour Cardiac Output (PiCCO) monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extravascular lung water index</measure>
    <time_frame>during the intervention</time_frame>
    <description>measured by Pulse Contour Cardiac Output (PiCCO) monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic vascular resistance index</measure>
    <time_frame>during the intervention</time_frame>
    <description>measured by Pulse Contour Cardiac Output (PiCCO) monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transcranial doppler flow velocities</measure>
    <time_frame>during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration</time_frame>
    <description>measured in the middle cerebral artery ipsilateral to the microdialysis probe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angiographic vasospasm</measure>
    <time_frame>immediately after the intervention</time_frame>
    <description>mild: vessel diameter from 60-99%, moderate: vessel diameter from 30-59%, severe: vessel diameter &lt;30% of the physiological lumen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral perfusion pressure</measure>
    <time_frame>during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration</time_frame>
    <description>measured continuously via intra-arterial and intracranial probes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of delayed ischemic strokes</measure>
    <time_frame>3-21 days following subarachnoid haemorrhage</time_frame>
    <description>ischemic strokes on CT scans</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Delayed Cerebral Ischemia</condition>
  <condition>Vasospasm, Cerebral</condition>
  <arm_group>
    <arm_group_label>oral nimodipine</arm_group_label>
    <description>60mg of nimodipine is orally administered every 4 h,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-venous nimodipine</arm_group_label>
    <description>nimodipine is continuously administered intra-venously, starting with 0.5 mg/h on day 1 and increased every day for 0.5 mg/h to a maximum dose of 2.0mg/h on day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-arterial nimodipine</arm_group_label>
    <description>during endovascular procedure 2mg of nimodipine is infused via a microcatheter into the internal carotid artery for 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
    <description>If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.</description>
    <arm_group_label>intra-arterial nimodipine</arm_group_label>
    <arm_group_label>intra-venous nimodipine</arm_group_label>
    <arm_group_label>oral nimodipine</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, cerebrospinal fluid, microdialysate&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring intensive care and bedside cerebral microdialysis for cerebral&#xD;
        neurochemical monitoring as standard care with a clinical indication for concomitant&#xD;
        treatment with either oral, intra-venous or intra-arterial nimodipin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient age &gt; 18 years&#xD;
&#xD;
          -  aneurysmal subarachnoid hemorrhage&#xD;
&#xD;
          -  sedated and mechanically ventilated&#xD;
&#xD;
          -  application of brain microdialysis as standard care (due to the severity of&#xD;
             subarachnoid haemorrhage or secondary deterioration)&#xD;
&#xD;
          -  oral, intra-venous or intra-arterial administration of nimodipine due to clinical&#xD;
             indication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication for nimodipine&#xD;
&#xD;
          -  no need of intensive care and bedside cerebral microdialysis as standard care&#xD;
&#xD;
          -  any disease considered relevant for proper performance of the study or risks to the&#xD;
             patient, at the discretion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthur Hosmann, MD PhD</last_name>
    <phone>+43/1/40400</phone>
    <phone_ext>25650</phone_ext>
    <email>arthur.hosmann@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Hosmann, MD PhD</last_name>
      <phone>+43/1/40400</phone>
      <phone_ext>25650</phone_ext>
      <email>arthur.hosmann@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Arthur Hosmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

